Human VEGF R3/FLT4 Protein (VGF-HM2R3)
|Recombinant Human VEGF R3/FLT4 Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Tyr25-Ile776.
|Vascular endothelial growth factor (VEGF) and its receptors VEGF-R1, -R2 and -R3 play important roles in tumor angiogenesis and are associated with poor prognosis in several solid tumors.VEGF-R1, -R2 and -R3 were highly expressed in CRC cells and stromal vessels. VEGF-R1 strong positive staining correlated with shorter survival after CRC surgery.
|VEGFR-3; FLT-4; LMPH1A; PCLFLT41; VEGFR3; FLT-41; PCL
|The protein has a predicted MW of 111.3 kDa. Due to glycosylation, the protein migrates to 135-155 kDa based on Tris-Bis PAGE result.
|Immobilized Human VEGF-C, His Tag at 1ug/ml (100ul/well) on the plate. Dose response curve for Human VEGF R3, hFc Tag with the EC50 of 17.9ng/ml determined by ELISA. See testing image for detail.
|> 95% as determined by Tris-Bis PAGE;> 95% as determined by HPLC
|Less than 1EU per ug by the LAL method.
|Shipped at ambient temperature.
|Lyophilized from 0.22um filtered solution in 50mM Tris, 150mM NaCl, 100mM Glycine (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization.
|Centrifuge the tube before opening. Reconstituting to a concentration more than 100 ug/ml is recommended. Dissolve the lyophilized protein in distilled water.
|Stability And Storage
|Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles.